0
October 1997, Vol 133, No. 10 >
Article | October 1997

Comparing Topical Scabietic Treatments Will Soon Become Extinct

Kristiina M. Burkhart; Craig N. Burkhart; Craig G. Burkhart, MS
[+] Author Affiliations

Department of Medicine Medical College of Ohio 5600 Monroe St, Suite 106B Sylvania, OH 43560


Arch Dermatol. 1997;133(10):1314-1314. doi:10.1001/archderm.1997.03890460140025
Text Size: A A A
Published online
Article
References
Comments

We noted the interchange between Franz et al1 and Downs2 in recent issues of the Archives concerning the available topical scabietic agents that are currently used. However, with the Food and Drug Administration's approval of ivermectin (Stromectol, Merck & Co Inc, West Point, Pa) in November 1996, a new era of scabietic therapeutics began. Ivermectin is an anthelmintic used extensively in veterinary medicine for a wide range of nematode, insect, and acarine parasites, including Sarcoptes scabiei in animals.3 We use this drug routinely every 2 months for all the Arabian horses on our farm to control any potential parasitic infection. In fact, ivermectin is sold over-the-counter at farm supply stores, tack shops, grain elevators, and via stock catalogs for animal use. The drug has also been used in more than 6 million people for diseases, including onchocerciasis, strongyloidiasis, loiasis, bancroftian filariasis, and cutaneous larva migrans.

There already

REFERENCES

1 +
Franz TJ, Lehman PA, Franz SF, Guin JD.  Comparative percutaneous absorption of lindane and permethrin . Arch Dermatol. 1996;;132:901-905.
2 +
Downs A.  Comparing antiscabies treatments . Arch Dermatol. 1997;;133:526.
3 +
Aubin F, Humbert P.  Ivermectin for crusted (Norwegian) scabies . N Engl J Med. 1995;;332:612.
4 +
Meinking TL, Taplin D, Hermida JL, et al.  The treatment of scabies with ivermectin . N Engl J Med. 1995;;333:26-30.
5 +
Dunne CL, Malone CJ, Whitworth JA.  A field study of the effects of ivermectin on ectoparasites of man . Trans R Soc Trop Med Hyg. 1991;;85:550-551.
6 +
Marty P, Gari-Toussaint M, Le Fichoux Y, Gaxotte P.  Efficacy of ivermectin in the treatment of an epidemic of sarcoptic scabies . Ann Trop Med Parasitol. 1994;;88:453.
7 +
Burkhart KM, Burkhart CN, Burkhart CG.  An epidemiologic and therapeutic reassessment of scabies: special focus on fomite transmission and the newly available ivermectin treatment . Infect Med. In press.
8 +
Barkwell R, Shields S.  Deaths associated with ivermectin treatment of scabies . Lancet. 1997;;349:1144-1145.

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

1 +
Franz TJ, Lehman PA, Franz SF, Guin JD.  Comparative percutaneous absorption of lindane and permethrin . Arch Dermatol. 1996;;132:901-905.
2 +
Downs A.  Comparing antiscabies treatments . Arch Dermatol. 1997;;133:526.
3 +
Aubin F, Humbert P.  Ivermectin for crusted (Norwegian) scabies . N Engl J Med. 1995;;332:612.
4 +
Meinking TL, Taplin D, Hermida JL, et al.  The treatment of scabies with ivermectin . N Engl J Med. 1995;;333:26-30.
5 +
Dunne CL, Malone CJ, Whitworth JA.  A field study of the effects of ivermectin on ectoparasites of man . Trans R Soc Trop Med Hyg. 1991;;85:550-551.
6 +
Marty P, Gari-Toussaint M, Le Fichoux Y, Gaxotte P.  Efficacy of ivermectin in the treatment of an epidemic of sarcoptic scabies . Ann Trop Med Parasitol. 1994;;88:453.
7 +
Burkhart KM, Burkhart CN, Burkhart CG.  An epidemiologic and therapeutic reassessment of scabies: special focus on fomite transmission and the newly available ivermectin treatment . Infect Med. In press.
8 +
Barkwell R, Shields S.  Deaths associated with ivermectin treatment of scabies . Lancet. 1997;;349:1144-1145.

Correspondence

Submit a Letter
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general journals
BMJ 2010;341:c5893-c1494.
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

© 2012 American Medical Association. All Rights Reserved.
Powered bySilverchair Information Systems